相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma During Therapy With Alemtuzumab for T-Cell Prolymphocytic Leukemia
Aliyah R. Sohani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy
Liuyan Jiang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
Peter Reimer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies
Eva Geissinger et al.
LEUKEMIA & LYMPHOMA (2009)
Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how?
Francesco d’Amore et al.
Current Hematologic Malignancy Reports (2009)
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Hanneke C. Kluin-Nelemans et al.
BLOOD (2008)
Hematopoietic SCT for peripheral T-cell lymphoma
A. Gutierrez et al.
BONE MARROW TRANSPLANTATION (2008)
Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma
Katja C. Weisel et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
C. Agostinelli et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Pharmacokinetics of alemtuzumab and the relevance in clinical practice
Thomas Elter et al.
LEUKEMIA & LYMPHOMA (2008)
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
S. M. Horwitz
Hematology-American Society of Hematology Education Program (2008)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Andrea Gallamini et al.
BLOOD (2007)
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
Jong Gwang Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
CD52 expression in non-mycotic T- and NK/T-cell lymphomas
Sheng-Tsung Chang et al.
LEUKEMIA & LYMPHOMA (2007)
Expression of CD52 in peripheral T-cell lymphoma
Pier Paolo Piccaluga et al.
HAEMATOLOGICA (2007)
Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2006)
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
G Enblad et al.
BLOOD (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:: results of the NHL-B1 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
SM O'Brien et al.
CANCER (2003)
Posttransplantation lymphoproliferative disorders
P Andreome et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
J Lundin et al.
BLOOD (2003)
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience
J Rodriguez et al.
ANNALS OF ONCOLOGY (2003)
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
CE Dearden et al.
BLOOD (2001)
分享论文
